Literature DB >> 2904393

Gastrin cell function in familial multiple endocrine neoplasia type I.

C B Lamers1, J I Rotter, J B Jansen.   

Abstract

Recent studies have suggested that patients with multiple endocrine neoplasia type I (MEN I) may have abnormal serum gastrin secretion in the absence of gastrin producing tumours. G-(gastrin) cell function by three provocation tests in 20 patients with hyperparathyroidism from six MEN I-families were studied: each patient was an obligate carrier of the MEN I-gene. The serum gastrin response to secretin was used to identify the presence of gastrinoma, that to a test meal of G-cell hyperfunction of the antral and/or duodenal mucosa, and that to bombesin to differentiate antral from duodenal G-cell hyperfunction. Seven patients had basal hypergastrinaemia and hyperchlorhydria. These patients had increased serum gastrin responses to secretin (p less than 0.01) and to bombesin (p less than 0.02), but normal postprandial responses. In the 13 normogastrinaemic patients the responses to the three stimuli were normal. In families with MEN-I gastrinoma is the only endocrine disorder accounting for abnormal gastrin secretion. G-cell function is normal in obligate carriers of the MEN I-gene.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2904393      PMCID: PMC1434020          DOI: 10.1136/gut.29.10.1358

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  27 in total

1.  The development of endocrinopathies in the prospective screening of two families with multiple endocrine adenopathy, type I.

Authors:  S R Friesen
Journal:  World J Surg       Date:  1979-11       Impact factor: 3.352

2.  Of gastrinomas and their management.

Authors:  E Passaro; B E Stabile
Journal:  Gastroenterology       Date:  1983-06       Impact factor: 22.682

3.  Secretin-stimulated serum gastrin levels in hyperparathyroid patients from families with multiple endocrine adenomatosis type I.

Authors:  C B Lamers; J T Buis; J van Tongeren
Journal:  Ann Intern Med       Date:  1977-06       Impact factor: 25.391

4.  Omeprazole in Zollinger-Ellison syndrome. Effects of a single dose and of long-term treatment in patients resistant to histamine H2-receptor antagonists.

Authors:  C B Lambers; T Lind; S Moberg; J B Jansen; L Olbe
Journal:  N Engl J Med       Date:  1984-03-22       Impact factor: 91.245

5.  A standardized meal stimulation test of the endocrine pancreas for early detection of pancreatic endocrine tumors in multiple endocrine neoplasia type 1 syndrome: five years experience.

Authors:  B Skogseid; K Oberg; L Benson; P G Lindgren; L E Lörelius; G Lundquist; L Wide; E Wilander
Journal:  J Clin Endocrinol Metab       Date:  1987-06       Impact factor: 5.958

6.  Clinical usefulness of the secretin provocation test.

Authors:  C B Lamers
Journal:  J Clin Gastroenterol       Date:  1981-09       Impact factor: 3.062

7.  Family studies of hypergastrinemic, hyperpepsinogenemic I duodenal ulcer.

Authors:  I L Taylor; J Calam; J I Rotter; C Vaillant; I M Samloff; A Cook; E Simkin; G J Dockray
Journal:  Ann Intern Med       Date:  1981-10       Impact factor: 25.391

Review 8.  Multiple endocrine neoplasia syndromes.

Authors:  C J Lips; H F Vasen; C B Lamers
Journal:  Crit Rev Oncol Hematol       Date:  1984       Impact factor: 6.312

9.  Hyperparathyroidism and gastroenteropancreatic hormone levels.

Authors:  W E Strodel; A I Vinik; F E Eckhauser; N W Thompson
Journal:  Surgery       Date:  1985-12       Impact factor: 3.982

10.  Effect of parathyroidectomy in patients with hyperparathyroidism, Zollinger-Ellison syndrome, and multiple endocrine neoplasia type I: a prospective study.

Authors:  J A Norton; M J Cornelius; J L Doppman; P N Maton; J D Gardner; R T Jensen
Journal:  Surgery       Date:  1987-12       Impact factor: 3.982

View more
  1 in total

1.  Diagnosis of Zollinger-Ellison syndrome in the era of PPIs, faulty gastrin assays, sensitive imaging and limited access to acid secretory testing.

Authors:  David C Metz; Guillaume Cadiot; Pierre Poitras; Tetsuhide Ito; Robert T Jensen
Journal:  Int J Endocr Oncol       Date:  2017-10-11
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.